MXPA05011432A - Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. - Google Patents

Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.

Info

Publication number
MXPA05011432A
MXPA05011432A MXPA05011432A MXPA05011432A MXPA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A
Authority
MX
Mexico
Prior art keywords
thrombin
mopidamole
treatment
dipyridamole
disorders caused
Prior art date
Application number
MXPA05011432A
Other languages
English (en)
Inventor
Victor L Serebruany
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA05011432A publication Critical patent/MXPA05011432A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se describe un metodo de tratamiento del cuerpo animal no humano o humano para tratar o prevenir desordenes originados por expresion de trombina elevada o receptor de trombina elevada, por ejemplo sindromes vasculares de enfermedad tromboembolica, o enfermedades proliferativas, cuyo metodo comprende administrar a un cuerpo animal no humano o humano en necesidad de tal tratamiento una cantidad eficaz de una composicion farmaceutica que contiene dipiridamol, mopidamol o una sal farmaceuticamente aceptable de los mismos, composiciones farmaceuticas correspondientes asi como tambien el uso de dipiridamol o mopidamol para la elaboracion de estas composiciones farmaceuticas.
MXPA05011432A 2003-04-24 2004-04-17 Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. MXPA05011432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46516803P 2003-04-24 2003-04-24
PCT/EP2004/004097 WO2004093881A2 (en) 2003-04-24 2004-04-17 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors

Publications (1)

Publication Number Publication Date
MXPA05011432A true MXPA05011432A (es) 2006-03-21

Family

ID=33311001

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011432A MXPA05011432A (es) 2003-04-24 2004-04-17 Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.

Country Status (12)

Country Link
US (3) US20050014770A1 (es)
EP (2) EP2062580A1 (es)
JP (1) JP2006524203A (es)
KR (1) KR20060007034A (es)
CN (1) CN1812792A (es)
AU (1) AU2004231306A1 (es)
BR (1) BRPI0409796A (es)
CA (1) CA2523157A1 (es)
MX (1) MXPA05011432A (es)
RU (1) RU2005136383A (es)
WO (1) WO2004093881A2 (es)
ZA (1) ZA200508016B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
BRPI0511054A (pt) 2004-05-13 2007-11-27 Boehringer Ingelheim Int uso de dipiridamola para o tratamento de resistência a inibidores plaquetários
US20090075949A1 (en) * 2004-10-25 2009-03-19 Wolfgang Eisert Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005028168B3 (de) 2005-06-17 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
EP2043632A2 (en) * 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New indications for direct thrombin inhibitors
AR062058A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Nuevas indicaciones pediatricas para los inhibidores directos de la trombina
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
EP2331096A1 (en) * 2008-08-19 2011-06-15 Boehringer Ingelheim International GmbH Dabigatran in tumour therapy
NZ592613A (en) * 2008-11-11 2013-06-28 Boehringer Ingelheim Int Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2011085473A1 (en) * 2010-01-13 2011-07-21 Linda Penn Treating cancer with statins and compounds having dipyridamole activity
CA3034874A1 (en) * 2015-10-15 2017-04-20 Moshe Rogosnitzky Low dose oral dipyridamole compositions and uses thereof
US20210277357A1 (en) * 2018-06-15 2021-09-09 Naing Bijaj Methods of detection of mechanically-activated platelet activation and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
GB1051218A (es) 1963-03-09
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
WO2002034248A2 (en) 2000-10-20 2002-05-02 Boehringer Ingelheim Pharmaceuticals, Inc. METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
JP2004518688A (ja) * 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
EP1250921A1 (en) 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
CA2496445A1 (en) * 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
CA2515266A1 (en) * 2003-02-07 2004-08-19 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders

Also Published As

Publication number Publication date
US20090192123A1 (en) 2009-07-30
EP1622621A2 (en) 2006-02-08
BRPI0409796A (pt) 2006-05-30
WO2004093881A3 (en) 2005-06-16
CA2523157A1 (en) 2004-11-04
US20050014770A1 (en) 2005-01-20
RU2005136383A (ru) 2007-06-10
WO2004093881A2 (en) 2004-11-04
AU2004231306A1 (en) 2004-11-04
CN1812792A (zh) 2006-08-02
EP2062580A1 (en) 2009-05-27
ZA200508016B (en) 2007-03-28
JP2006524203A (ja) 2006-10-26
US20070105753A1 (en) 2007-05-10
KR20060007034A (ko) 2006-01-23

Similar Documents

Publication Publication Date Title
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
BR0107732A (pt) Método para prevenir ou tratar uma doença
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
UA92584C2 (ru) Применение мелоксикама для лечения респираторных заболеваний у свиней
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
HK1086011A1 (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
SE0400184D0 (sv) New therapeutical use
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
TNSN07474A1 (en) Dosage regimen for prasugrel
JP2004537500A5 (es)
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
ATE392901T1 (de) Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal